β blocker heart failure trials: concomitant medication
↵8-150 CIBIS II permitted amiodarone (which the other two trials did not)—15% received this drug;
↵8-151 loop diuretic;
↵8-152 96% ACE inhibitor or angiotensin II receptor antagonist;
↵8-153 antiplatelet agents in CIBIS II;
↵8-154 direct acting vasodilators in USCP.